Correction to “Benefit of axicabtagene ciloleucel vs chemoimmunotherapy in older patients and/or patients with poor <scp>ECOG</scp> performance status with relapsed or refractory large B‐cell lymphoma after 2 or more lines of prior therapy”

Authors: Abstract: No abstract found.

Published: 2024-05-07

DOI: HTTPS://DOI.ORG/10.1002/ajh.27356

Keywords: No keywords found.

Abstract:
No abstract found.

Source: